Design of new drugs for medullary thyroid carcinoma
Medullary thyroid carcinoma (MTC) is one of the common malignant endocrine tumors, which seriously affects human health. Although surgical resection offers a potentially curative therapeutic option to some MTC patients, most patients do not benefit from it due to the difficulty to access the tumors...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.993725/full |
_version_ | 1797985226942578688 |
---|---|
author | Yanqing Li Yanqing Li Ziyu Luo Ziyu Luo Xinxing Wang Songtao Zhang Songtao Zhang Hu Hei Hu Hei Jianwu Qin Jianwu Qin |
author_facet | Yanqing Li Yanqing Li Ziyu Luo Ziyu Luo Xinxing Wang Songtao Zhang Songtao Zhang Hu Hei Hu Hei Jianwu Qin Jianwu Qin |
author_sort | Yanqing Li |
collection | DOAJ |
description | Medullary thyroid carcinoma (MTC) is one of the common malignant endocrine tumors, which seriously affects human health. Although surgical resection offers a potentially curative therapeutic option to some MTC patients, most patients do not benefit from it due to the difficulty to access the tumors and tumor metastasis. The survival rate of MTC patients has improved with the recent advances in the research, which has improved our understanding of the molecular mechanism underlying MTC and enabled the development and approval of novel targeted drugs. In this article, we reviewed the molecular mechanisms related to MTC progression and the principle for the design of molecular targeted drugs, and proposed some future directions for prospective studies exploring targeted drugs for MTC. |
first_indexed | 2024-04-11T07:15:02Z |
format | Article |
id | doaj.art-ea095d602b7a4f1d907297e30c6fe3b1 |
institution | Directory Open Access Journal |
issn | 2234-943X |
language | English |
last_indexed | 2024-04-11T07:15:02Z |
publishDate | 2022-12-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Oncology |
spelling | doaj.art-ea095d602b7a4f1d907297e30c6fe3b12022-12-22T04:38:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.993725993725Design of new drugs for medullary thyroid carcinomaYanqing Li0Yanqing Li1Ziyu Luo2Ziyu Luo3Xinxing Wang4Songtao Zhang5Songtao Zhang6Hu Hei7Hu Hei8Jianwu Qin9Jianwu Qin10Department of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaThe Medical School of Zhengzhou University, Zhengzhou, ChinaDepartment of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaThe Medical School of Zhengzhou University, Zhengzhou, ChinaDepartment of Pain and Rehabilitation and Palliative Medicine, Henan Cancer Hospital, Zhengzhou, ChinaDepartment of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaThe Medical School of Zhengzhou University, Zhengzhou, ChinaDepartment of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaThe Medical School of Zhengzhou University, Zhengzhou, ChinaDepartment of Thyroid and Neck, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, ChinaThe Medical School of Zhengzhou University, Zhengzhou, ChinaMedullary thyroid carcinoma (MTC) is one of the common malignant endocrine tumors, which seriously affects human health. Although surgical resection offers a potentially curative therapeutic option to some MTC patients, most patients do not benefit from it due to the difficulty to access the tumors and tumor metastasis. The survival rate of MTC patients has improved with the recent advances in the research, which has improved our understanding of the molecular mechanism underlying MTC and enabled the development and approval of novel targeted drugs. In this article, we reviewed the molecular mechanisms related to MTC progression and the principle for the design of molecular targeted drugs, and proposed some future directions for prospective studies exploring targeted drugs for MTC.https://www.frontiersin.org/articles/10.3389/fonc.2022.993725/fullmedullary thyroid carcinomatargeted drugmolecular mechanismdesigned principleprogression |
spellingShingle | Yanqing Li Yanqing Li Ziyu Luo Ziyu Luo Xinxing Wang Songtao Zhang Songtao Zhang Hu Hei Hu Hei Jianwu Qin Jianwu Qin Design of new drugs for medullary thyroid carcinoma Frontiers in Oncology medullary thyroid carcinoma targeted drug molecular mechanism designed principle progression |
title | Design of new drugs for medullary thyroid carcinoma |
title_full | Design of new drugs for medullary thyroid carcinoma |
title_fullStr | Design of new drugs for medullary thyroid carcinoma |
title_full_unstemmed | Design of new drugs for medullary thyroid carcinoma |
title_short | Design of new drugs for medullary thyroid carcinoma |
title_sort | design of new drugs for medullary thyroid carcinoma |
topic | medullary thyroid carcinoma targeted drug molecular mechanism designed principle progression |
url | https://www.frontiersin.org/articles/10.3389/fonc.2022.993725/full |
work_keys_str_mv | AT yanqingli designofnewdrugsformedullarythyroidcarcinoma AT yanqingli designofnewdrugsformedullarythyroidcarcinoma AT ziyuluo designofnewdrugsformedullarythyroidcarcinoma AT ziyuluo designofnewdrugsformedullarythyroidcarcinoma AT xinxingwang designofnewdrugsformedullarythyroidcarcinoma AT songtaozhang designofnewdrugsformedullarythyroidcarcinoma AT songtaozhang designofnewdrugsformedullarythyroidcarcinoma AT huhei designofnewdrugsformedullarythyroidcarcinoma AT huhei designofnewdrugsformedullarythyroidcarcinoma AT jianwuqin designofnewdrugsformedullarythyroidcarcinoma AT jianwuqin designofnewdrugsformedullarythyroidcarcinoma |